COVID-19-related thyroid conditions (Review).
COVID-19
interleukin-6
thyroid
thyroiditis
thyrotoxicosis
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
08
02
2021
accepted:
10
03
2021
entrez:
26
5
2021
pubmed:
27
5
2021
medline:
27
5
2021
Statut:
ppublish
Résumé
In patients who were not previously diagnosed with any thyroid conditions, the scenario of COVID-19-related anomalies of the hypothalamus-pituitary-thyroid axes may include either: A process of central thyroid stimulating hormone (TSH) disturbances via virus-related hypophysitis; an atypical type of subacute thyroiditis which is connected to the virus spread or to excessive cytokine production including a destructive process with irreversible damage of the gland or low T3 (triiodothyronine) syndrome (so called non-thyroid illness syndrome) which is not specifically related to the COVID-19 infection, but which is associated with a very severe illness status. Our objective here was to briefly review thyroid changes due to the COVID-19 infection. Ongoing assessment of the effects of the COVID-19 pandemic will reveal more information on coronavirus-induced thyroid conditions. Routine thyroid assays performed in patients with severe infection/at acute phase of COVID-19 are encouraged in order to detect thyrotoxicosis. After recovery, thyroid function should be assessed to identify potential hypothyroidism. There remain unanswered questions related to the prognostic value of interleukin-6 in infected patients, especially in cases with cytokine storm, and the necessity of thyroid hormone replacement in subjects with hypophysitis-related central hypothyroidism.
Identifiants
pubmed: 34035853
doi: 10.3892/etm.2021.10188
pii: ETM-0-0-10188
pmc: PMC8135141
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
756Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Clin Obes. 2020 Dec;10(6):e12403
pubmed: 32857454
BMJ Case Rep. 2020 Aug 25;13(8):
pubmed: 32843467
Front Pharmacol. 2020 Jul 17;11:1093
pubmed: 32765283
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 32232480
Eur J Endocrinol. 2020 Jul;183(1):G41-G48
pubmed: 32438345
Int J Environ Res Public Health. 2020 Sep 11;17(18):
pubmed: 32932954
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1841-1845
pubmed: 32971511
J Endocrinol Invest. 2021 May;44(5):1065-1073
pubmed: 32876925
Ophthalmic Plast Reconstr Surg. 2020 Jul/Aug;36(4):418-419
pubmed: 32658134
Endocr Metab Immune Disord Drug Targets. 2020 Sep 05;:
pubmed: 32888287
J Endocrinol Invest. 2020 Aug;43(8):1171-1172
pubmed: 32488726
Ann Rheum Dis. 2021 Jan;80(1):88-95
pubmed: 32978237
Elife. 2020 Sep 15;9:
pubmed: 32930095
Endocr Res. 2020 Aug;45(3):210-215
pubmed: 32628899
Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):831-836
pubmed: 32965559
J Clin Endocrinol Metab. 2020 Dec 1;105(12):
pubmed: 32929476
J Pak Med Assoc. 2020 May;70(Suppl 3)(5):S83-S86
pubmed: 32515380
Endocrine. 2020 May;68(2):251-252
pubmed: 32346813
Rev Endocr Metab Disord. 2020 Dec;21(4):495-507
pubmed: 32643004
J Pak Med Assoc. 2020 Jun;70(6):954-955
pubmed: 32810084
Trials. 2020 Jun 26;21(1):573
pubmed: 32586399
J Endocrinol Invest. 2020 Aug;43(8):1141-1147
pubmed: 32335855
Thyroid. 2021 Jan;31(1):8-11
pubmed: 32600165
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32780854
Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741
pubmed: 32738929
Exp Ther Med. 2020 Oct;20(4):3389-3393
pubmed: 32905095
J Endocrinol. 2020 Nov;247(2):R45-R62
pubmed: 32966970
Endocrine. 2020 Oct;70(1):1-5
pubmed: 32754886
Eur J Endocrinol. 2020 Jul;183(1):G33-G39
pubmed: 32438340
J Endocrinol Invest. 2020 Aug;43(8):1169-1170
pubmed: 32488724
Acta Biomed. 2020 Sep 07;91(3):e2020033
pubmed: 32921727
Endocrinology. 2020 Sep 1;161(9):
pubmed: 32652001
Tex Med. 2020 Jul 1;116(7):4-5
pubmed: 32872703
J Endocrinol Invest. 2020 Aug;43(8):1173-1174
pubmed: 32504458
J Endocrinol Invest. 2020 Jul;43(7):1027-1031
pubmed: 32361826
Maturitas. 2009 Jan 20;62(1):98-102
pubmed: 19110385
Adv Rheumatol. 2020 Sep 22;60(1):50
pubmed: 32962761
Int J Mol Med. 2020 Jul;46(1):3-16
pubmed: 32377694
Eur J Endocrinol. 2020 Oct;183(4):381-387
pubmed: 32698147
Pan Afr Med J. 2020 Jul 06;36:158
pubmed: 32874422
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 32436948
Rev Med Virol. 2021 Mar;31(2):e2159
pubmed: 32856339
Front Endocrinol (Lausanne). 2019 Jun 04;10:350
pubmed: 31214123
FEBS Open Bio. 2020 Nov;10(11):2363-2374
pubmed: 32970391
Ann Endocrinol (Paris). 2020 Oct;81(5):507-510
pubmed: 32950466
Lancet Diabetes Endocrinol. 2020 Jun;8(6):472-473
pubmed: 32334645
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
Biosci Rep. 2020 Aug 28;40(8):
pubmed: 32725148
Am J Trop Med Hyg. 2020 Nov;103(5):1783-1796
pubmed: 32940201
Int J Mol Med. 2020 Jun;45(6):1631-1643
pubmed: 32236624
Evid Based Dent. 2020 Sep;21(3):84-86
pubmed: 32978532